Continued remission maintained with decitabine monotherapy in an elderly patient with TP53 multi-hit acute myeloid leukemia relapsed after allogeneic transplantation.
Not available.
We have 4 of 67 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Not available.
It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.